The companies intend to integrate the BD Rhapsody™ System with the Opentrons Flex® platform, as well as develop verified protocols, allowing scientists to perform hands-free workflows with their single-cell multiomics experiments. A cornerstone of the collaboration is the development of an automation-compatible module for the BD Rhapsody™ System that will enable the steps of next-generation sequencing library preparation and cell capture to be automated.
“This collaboration brings together the long-standing expertise of BD in the field of single-cell multiomics with the flexible and open automation ecosystem of Opentrons,” said James Atwood, PhD, CEO of Opentrons Labworks. “By combining our hardware platforms, we are making it easier and more cost-effective for labs everywhere, across basic and translational research, to perform cutting-edge single-cell sequencing at scale.”
Early access opportunities for interested labs will be available soon. To learn more about the collaboration and the early access program, visit Opentrons (Booth 635) and BD (Booth 447) at the upcoming American Society of Human Genetics (ASHG) Annual Meeting in Boston, from October 14-18, 2025.
Learn more about the BD Rhapsody™ HT Xpress System.